Category: Analysis - Page 3 - Psychedelic Alpha

Billionaire Investor Antonio Gracias Plots $100M Lykos Takeover with Doblin’s Backing

Post published:January 10, 2025
Post category:Analysis News Pα+

From Fringe to Focus: APA’s American Journal of Psychiatry Publishes Special Issue on Psychedelics

Post published:January 7, 2025
Post category:Analysis News Pα+

Psychedelic Alpha’s Top 11 Stories from 2024

Post published:December 26, 2024
Post category:2024 Year in Review Analysis News

SCOOP: PSFC’s $130M Roadmap to Shape the Future of Psychedelic Philanthropy

Post published:December 20, 2024
Post category:Analysis News Pα+

Psychedelic Drug Development Under Trump 2.0: Health Nominees Signal Uncertain Future

Post published:November 30, 2024
Post category:Analysis News Pα+

Q3’24 Survey: What are Psychedelics Investors Concerned About?

Post published:November 27, 2024
Post category:Analysis News Pα+

Interviews: Meet the Team Who Challenged the DEA on DOI and DOC

Post published:November 26, 2024
Post category:Analysis News

Q3’24 Survey: What are Psychedelics Investors Excited About?

Post published:November 25, 2024
Post category:Analysis News Pα+

Psychedelic Investor Survey Q3 2024

Post published:November 19, 2024
Post category:Analysis News

Dispatch From the DEA: DOI and DOC on Trial As Scientists Challenge Psychedelic Scheduling Bid

Post published:November 18, 2024
Post category:Analysis News

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.